Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Reports encouraging new clinical data for ROCK2 inhibitor. Says its ROCK2 inhibitor RXC007 being developed for idiopathic pulmonary fibrosis has excellent safety and pharmacokinetic profile, with no adverse events following single dose of 2 to 40 milligram. Redx also plans to commence a global Phase 2 monotherapy programme with RXC004 in three cancer types with Wnt-ligand dependent tumours: microsatellite stable metastatic colorectal cancer, pancreatic cancer and biliary tract cancer. RXC004 is also currently being investigated in a Phase 1 study in combination with the anti-PD-1antibody nivolumab, it adds.
Current stock price: 80.00 pence
Year-to-date change: up 26%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
